Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18196027 | 1.00 | HIF1A (0.50) | HIF1AEPAS1 | |
| SCHEMBL1231200 | 1.00 | HIF1A (0.50) | HIF1AEPAS1 | |
| SCHEMBL21434328 | 1.00 | HIF1A (0.50) | HIF1AEPAS1 | |
| SCHEMBL8616760 | 0.86 | PDCD4 (0.42) | HIF1AEPAS1 | |
| SCHEMBL12315508 | 0.82 | HIF1A (0.62) | HIF1AEPAS1 | |
| SCHEMBL14500948 | 0.78 | HIF1A (0.76) | HIF1AEPAS1 | |
| SCHEMBL14500959 | 0.78 | HIF1A (0.76) | HIF1AEPAS1 | |
| SCHEMBL14500933 | 0.78 | HIF1A (0.76) | HIF1AEPAS1 | |
| SCHEMBL14500947 | 0.78 | HIF1A (0.76) | HIF1AEPAS1 | |
| SCHEMBL17867390 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| CN-114555124-A | Pharmaceutical co-crystal salt formulation | 瑟拉诺沃控股有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-114041068-A | OFDM radar sensor system with actively forwarding repeaters | 罗伯特·博世有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-10370654-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180320170-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2018-11-08 | — | — | US | disclosed |
| US-9944925-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. | 2018-04-17 | — | — | US | disclosed |
| US-20160186168-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2016-06-30 | — | — | US | disclosed |
| EP-3027754-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | enEvolv, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015017866-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-20090192220-A1 | TREATMENT FOR SOLID TUMORS | ORE PHARMACEUTICALS INC. (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192220-A1 | TREATMENT FOR SOLID TUMORS | ACAT2, ACAT1, APRT | HIF1A 25/4885EPAS1 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.